Huifen Zhou

Mrs. Huifen Zhou


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
LYLi Yu
Li Yu
ZYZhang Yangyang
Zhang Yangyang
QCQianqian Chen
Qianqian Chen
YHYu He
Yu He
HZHuifen Zhou
Huifen Zhou
JYJiehong Yang
Jiehong Yang
Formononetin is a type of phytoestrogen obtained from the Chinese medical herb Red Clover. It exhibits anti-neoplastic hepatoprotective, and neuroprotective properties. However, the anti-inflammatory effect of formononetin in cerebral ischemia-reperfusion injury has not been reported. To explore the potential mechanism of action of formononetin in cerebral ischemia-reperfusion injury with regard to the JAK2/STAT3 signaling pathway. Male SD rats were used to establish a middle cerebral artery occlusion (MCAO) model and randomly divided into 5 groups: Sham, MCAO, JAK2 Inhibitor (Ag490), Formononetin, Inhibitor + Formononetin. The protective effect of formononetin in MCAO rats was detected by performing neurological deficit testing, TTC staining, H&E staining, Nissl staining, ELISA, RT-PCR, western blotting and immunofluorescence. Formononetin significantly alleviated the neurological deficit and the pathological state of brain tissues, and reduced the volume of cerebral infarction, levels of IL-18 and TNF-α inflammatory factors in plasma, mRNA levels of IL-6 and IL-1β in rat brain tissue, and the protein levels of p-JAK2, p-STAT3, NLRP3, ASC, cl-Caspase-1, and cl-IL-1β in the MCAO rat brain tissue. Formononetin has anti-inflammatory effects. It may inhibit the relevant targets in the JAK2/STAT3 signaling pathway, thereby having a certain protective effect against cerebral ischemia-reperfusion injury.

7 September 2022 in Ageing Research Reviews
Verified
Journal Article
Closed access
WLWentao Li
Wentao Li
CSChongyu Shao
Chongyu Shao
HZHuifen Zhou
Huifen Zhou
HDHaixia Du
Haixia Du
HCHaiyang Chen
Haiyang Chen
YHYu He
Yu He

27 January 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YYYuting Yang
Yuting Yang
YHYu He
Yu He
XWXiaoyu Wei
Xiaoyu Wei
HWHaitong Wan
Haitong Wan
ZDZhishan Ding
Zhishan Ding
HZHuifen Zhou
Huifen Zhou
Salvianolic acid C (SAC) is a major bioactive component of Salvia miltiorrhiza Bunge (Danshen), a Chinese herb for treating ischemic stroke (IS). However, the mechanism by which SAC affects the IS has not yet been evaluated, thus a network pharmacology integrated molecular docking strategy was performed to systematically evaluate its pharmacological mechanisms, which were further validated in rats with cerebral ischemia. A total of 361 potential SAC-related targets were predicted by SwissTargetPrediction and PharmMapper, and a total of 443 IS-related targets were obtained from DisGeNET, DrugBank, OMIM, and Therapeutic Target database (TTD) databases. SAC-related targets were hit by the 60 targets associated with IS. By Gene ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment combined with the protein-protein interaction (PPI) network and cytoHubba plug-ins, nine related signaling pathways (proteoglycans in cancer, pathways in cancer, PI3K-Akt signaling pathway, Focal adhesion, etc.), and 20 hub genes were identified. Consequently, molecular docking indicated that SAC may interact with the nine targets (F2, MMP7, KDR, IGF1, REN, PPARG, PLG, ACE and MMP1). Four of the target proteins (VEGFR2, MMP1, PPARγ and IGF1) were verified using western blot. This study comprehensively analyzed pathways and targets related to the treatment of IS by SAC. The results of western blot also confirmed that the SAC against IS is mainly related to anti-inflammatory and angiogenesis, which provides a reference for us to find and explore the effective anti-IS drugs.

1 October 2020 in Pharmacological Research
Verified
Journal Article
Closed access
YZYu Zhao
Yu Zhao
JYJiehong Yang
Jiehong Yang
CLChang Li
Chang Li
GZGuoying Zhou
Guoying Zhou
HWHaofang Wan
Haofang Wan
HZHuifen Zhou
Huifen Zhou

1 April 2015 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
MZMengkai Zheng
Mengkai Zheng
HZHuifen Zhou
Huifen Zhou
HWHaitong Wan
Haitong Wan
YCYu-Lin Chen
Yu-Lin Chen
YHYu He
Yu He

1 January 2018 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JWJiayang Wan
Jiayang Wan
HWHaofang Wan
Haofang Wan
RYRongbin Yang
Rongbin Yang
HWHaitong Wan
Haitong Wan
JYJiehong Yang
Jiehong Yang
HZHuifen Zhou
Huifen Zhou